Retension Pharmaceuticals, Inc. (RTSN)

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing drugs for high blood pressure and other heart and blood vessel diseases. Its candidate RTN-001 is an oral small molecule that inhibits phosphodiesterase-5 and is designed to lower blood pressure by boosting nitric oxide signaling. The company was incorporated in 2023 and is based in Falls Church, Virginia.